Rebecca Kusko
Pre-Doctoral Trainee
Boston University School of Medicine, Graduate Medical Sciences
Dept of Genetics & Genomics

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Sakkiah S, Guo W, Pan B, Kusko R, Tong W, Hong H. Computational prediction models for assessing endocrine disrupting potential of chemicals. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2019 Jan 11; 1-27. PMID: 30633647.
  2. Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Mol Neurodegener. 2018 05 21; 13(1):25. PMID: 29783994.
  3. Sakkiah S, Kusko R, Pan B, Guo W, Ge W, Tong W, Hong H. Structural Changes Due to Antagonist Binding in Ligand Binding Pocket of Androgen Receptor Elucidated Through Molecular Dynamics Simulations. Front Pharmacol. 2018; 9:492. PMID: 29867496.
  4. Brothers JF, Ung M, Escalante-Chong R, Ross J, Zhang J, Cha Y, Lysaght A, Funt J, Kusko R. Integrity, standards, and QC-related issues with big data in pre-clinical drug discovery. Biochem Pharmacol. 2018 06; 152:84-93. PMID: 29551586.
  5. Shi L, Kusko R, Wolfinger RD, Haibe-Kains B, Fischer M, Sansone SA, Mason CE, Furlanello C, Jones WD, Ning B, Tong W. The international MAQC Society launches to enhance reproducibility of high-throughput technologies. Nat Biotechnol. 2017 Dec 08; 35(12):1127-1128. PMID: 29220036.
  6. Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, Hayden MR, Pouladi MA. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight. 2017 Dec 07; 2(23). PMID: 29212949.
  7. Ross CJ, Towfic F, Shankar J, Laifenfeld D, Thoma M, Davis M, Weiner B, Kusko R, Zeskind B, Knappertz V, Grossman I, Hayden MR. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. Genome Med. 2017 May 31; 9(1):50. PMID: 28569182.
  8. Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, Papapetropoulos S, Grossman I, Laifenfeld D. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol. 2018 01; 175(2):168-180. PMID: 28369768; DOI: 10.1111/bph.13798;.
  9. Towfic F, Kusko R, Zeskind B. Letter to the Editor response: Nygaard et al. Biostatistics. 2017 Apr 01; 18(2):197-199. PMID: 27780809; DOI: 10.1093/biostatistics/kxw031;.
  10. Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, Boothman DA. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. Cancer Cell. 2016 Dec 12; 30(6):940-952. PMID: 27960087; DOI: 10.1016/j.ccell.2016.11.006;.
Showing 10 of 16 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 16 publications over 7 distinct years, with a maximum of 5 publications in 2017

Contact for Mentoring:

75 E. Newton St Evans Building
Boston MA 02118
Google Map

Kusko's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department